{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:03:23Z","timestamp":1791083003972,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National High Level Hospital Clinical Research Funding","award":["2024-NHLHCRF-PYII-22"],"award-info":[{"award-number":["2024-NHLHCRF-PYII-22"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01913-0","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T05:54:47Z","timestamp":1732514087000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database"],"prefix":"10.1186","volume":"25","author":[{"given":"Wen-Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Fa","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"issue":"9406","key":"1913_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/s0140-6736(04)15440-8","volume":"363","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD (2004) Migraine. Lancet 363(9406):381\u2013391. https:\/\/doi.org\/10.1016\/s0140-6736(04)15440-8","journal-title":"Lancet"},{"issue":"1","key":"1913_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s10194-024-01882-4","volume":"25","author":"ACT Tam","year":"2024","unstructured":"Tam ACT, Naik H, Trenaman L, Lynd L, Zhang W (2024) Health-related quality of life among women and men living with migraine: a Canada-wide cross-sectional study. J Headache Pain 25(1):170. https:\/\/doi.org\/10.1186\/s10194-024-01882-4","journal-title":"J Headache Pain"},{"issue":"10283","key":"1913_CR3","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/s0140-6736(20)32160-7","volume":"397","author":"M Ashina","year":"2021","unstructured":"Ashina M, Katsarava Z, Do TP et al (2021) Migraine: epidemiology and systems of care. Lancet 397(10283):1485\u20131495. https:\/\/doi.org\/10.1016\/s0140-6736(20)32160-7","journal-title":"Lancet"},{"key":"1913_CR4","doi-asserted-by":"publisher","unstructured":"Global regional, national burden of neurological disorders 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x","DOI":"10.1016\/s1474-4422(18)30499-x"},{"issue":"1","key":"1913_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s10194-016-0699-5","volume":"17","author":"TJ Steiner","year":"2016","unstructured":"Steiner TJ, Stovner LJ, Vos T (2016) GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain 17(1):104. https:\/\/doi.org\/10.1186\/s10194-016-0699-5","journal-title":"J Headache Pain"},{"key":"1913_CR6","doi-asserted-by":"publisher","unstructured":"Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u2013381. https:\/\/doi.org\/10.1016\/s1474-4422(24)00038-3","DOI":"10.1016\/s1474-4422(24)00038-3"},{"issue":"5","key":"1913_CR7","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/j.pain.0000000000001801","volume":"161","author":"A Labastida-Ram\u00edrez","year":"2020","unstructured":"Labastida-Ram\u00edrez A, Rubio-Beltr\u00e1n E, Haanes KA et al (2020) Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system. Pain 161(5):1092\u20131099. https:\/\/doi.org\/10.1097\/j.pain.0000000000001801","journal-title":"Pain"},{"issue":"12","key":"1913_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/0165-6147(91)90630-b","volume":"12","author":"PP Humphrey","year":"1991","unstructured":"Humphrey PP, Feniuk W (1991) Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 12(12):444\u2013446. https:\/\/doi.org\/10.1016\/0165-6147(91)90630-b","journal-title":"Trends Pharmacol Sci"},{"key":"1913_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1749-6632.1990.tb16912.x","volume":"600","author":"PP Humphrey","year":"1990","unstructured":"Humphrey PP, Feniuk W, Perren MJ, Beresford IJ, Skingle M, Whalley ET (1990) Serotonin and migraine. Ann N Y Acad Sci 600:587\u201398; discussion 598-600. https:\/\/doi.org\/10.1111\/j.1749-6632.1990.tb16912.x","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"1913_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","volume":"22","author":"MD Ferrari","year":"2002","unstructured":"Ferrari MD, Goadsby PJ, Roon KI, Lipton RB (2002) Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22(8):633\u2013658. https:\/\/doi.org\/10.1046\/j.1468-2982.2002.00404.x","journal-title":"Cephalalgia"},{"issue":"1","key":"1913_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s10194-022-01502-z","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Lampl C, Amin FM et al (2022) European Headache Federation (EHF) consensus on the definition of effective treatment of a migraine attack and of triptan failure. J Headache Pain 23(1):133. https:\/\/doi.org\/10.1186\/s10194-022-01502-z","journal-title":"J Headache Pain"},{"issue":"10","key":"1913_CR12","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s11916-023-01151-0","volume":"27","author":"EE Ingram","year":"2023","unstructured":"Ingram EE, Bocklud BE, Corley SC et al (2023) Non-CGRP Antagonist\/Non-Triptan options for Migraine Disease Treatment: clinical considerations. Curr Pain Headache Rep 27(10):497\u2013502. https:\/\/doi.org\/10.1007\/s11916-023-01151-0","journal-title":"Curr Pain Headache Rep"},{"issue":"10","key":"1913_CR13","doi-asserted-by":"publisher","first-page":"840","DOI":"10.7326\/0003-4819-137-10-200211190-00014","volume":"137","author":"V Snow","year":"2002","unstructured":"Snow V, Weiss K, Wall EM, Mottur-Pilson C (2002) Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 137(10):840\u2013849. https:\/\/doi.org\/10.7326\/0003-4819-137-10-200211190-00014","journal-title":"Ann Intern Med"},{"issue":"Suppl 4","key":"1913_CR14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/head.12601","volume":"55","author":"C Cameron","year":"2015","unstructured":"Cameron C, Kelly S, Hsieh SC et al (2015) Triptans in the Acute treatment of migraine: a systematic review and network Meta-analysis. Headache 55(Suppl 4):221\u2013235. https:\/\/doi.org\/10.1111\/head.12601","journal-title":"Headache"},{"issue":"5","key":"1913_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/head.14304","volume":"62","author":"K Zebenholzer","year":"2022","unstructured":"Zebenholzer K, Gall W, Gleiss A, Pavelic AR, W\u00f6ber C (2022) Triptans and vascular comorbidity in persons over fifty: findings from a nationwide insurance database - A cohort study. Headache 62(5):604\u2013612. https:\/\/doi.org\/10.1111\/head.14304","journal-title":"Headache"},{"issue":"3","key":"1913_CR16","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/jamia\/ocv153","volume":"23","author":"TA Kass-Hout","year":"2016","unstructured":"Kass-Hout TA, Xu Z, Mohebbi M et al (2016) OpenFDA: an innovative platform providing access to a wealth of FDA\u2019s publicly available data. J Am Med Inf Assoc 23(3):596\u2013600. https:\/\/doi.org\/10.1093\/jamia\/ocv153","journal-title":"J Am Med Inf Assoc"},{"issue":"1","key":"1913_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0333102413499649","volume":"34","author":"G Roberto","year":"2014","unstructured":"Roberto G, Piccinni C, D\u2019Alessandro R, Poluzzi E (2014) Triptans and serious adverse vascular events: data mining of the FDA adverse event reporting System database. Cephalalgia 34(1):5\u201313. https:\/\/doi.org\/10.1177\/0333102413499649","journal-title":"Cephalalgia"},{"key":"1913_CR18","doi-asserted-by":"publisher","unstructured":"Sharma P, Varghese Gupta S, Bhatt P et al (2024) Cardiovascular adverse events associated with triptans for treatment of migraine: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Can J Physiol Pharmacol. https:\/\/doi.org\/10.1139\/cjpp-2024-0117","DOI":"10.1139\/cjpp-2024-0117"},{"issue":"3","key":"1913_CR19","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s11096-022-01514-4","volume":"45","author":"L Wei","year":"2023","unstructured":"Wei L, Tian Y, Chen X et al (2023) Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration adverse event reporting System database. Int J Clin Pharm 45(3):622\u2013629. https:\/\/doi.org\/10.1007\/s11096-022-01514-4","journal-title":"Int J Clin Pharm"},{"issue":"2","key":"1913_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm R, H\u00f6cker J, Cascorbi I, Herdegen T (2012) OpenVigil\u2013free eyeballs on AERS pharmacovigilance data. Nat Biotechnol 30(2):137\u2013138. https:\/\/doi.org\/10.1038\/nbt.2113","journal-title":"Nat Biotechnol"},{"key":"1913_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/dhps.S391857","volume":"15","author":"TA Simon","year":"2023","unstructured":"Simon TA, Simon JH, Heaning EG, Gomez-Caminero A, Marcu JP (2023) Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: evaluating Case Report Data in the Food and Drug Administration adverse event reporting system (FAERS) database. Drug Healthc Patient Saf 15:25\u201338. https:\/\/doi.org\/10.2147\/dhps.S391857","journal-title":"Drug Healthc Patient Saf"},{"key":"1913_CR22","doi-asserted-by":"publisher","unstructured":"Noguchi Y, Tachi T, Teramachi H (2021) Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief Bioinform 22(6). https:\/\/doi.org\/10.1093\/bib\/bbab347","DOI":"10.1093\/bib\/bbab347"},{"issue":"6","key":"1913_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483\u2013486. https:\/\/doi.org\/10.1002\/pds.677","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1913_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11095-020-02801-3","volume":"37","author":"Y Noguchi","year":"2020","unstructured":"Noguchi Y, Tachi T, Teramachi H (2020) Comparison of Signal Detection Algorithms based on frequency statistical model for drug-drug Interaction using spontaneous Reporting systems. Pharm Res 37(5):86. https:\/\/doi.org\/10.1007\/s11095-020-02801-3","journal-title":"Pharm Res"},{"issue":"4","key":"1913_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/add.16081","volume":"118","author":"M Robert","year":"2023","unstructured":"Robert M, Jouanjus E, Khouri C, Fouilh\u00e9 Sam-La\u00ef N, Revol B (2023) The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database. Addiction 118(4):771\u2013775. https:\/\/doi.org\/10.1111\/add.16081","journal-title":"Addiction"},{"key":"1913_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.990241","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Zhang Q, He X, Liu Y, Wu P, Chen L (2022) Fluoroquinolone-associated suspected tendonitis and tendon rupture: a pharmacovigilance analysis from 2016 to 2021 based on the FAERS database. Front Pharmacol 13:990241. https:\/\/doi.org\/10.3389\/fphar.2022.990241","journal-title":"Front Pharmacol"},{"issue":"11","key":"1913_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294236","volume":"18","author":"D Tang","year":"2023","unstructured":"Tang D, Chen M, Huang X et al (2023) SRplot: a free online platform for data visualization and graphing. PLoS One 18(11):e0294236. https:\/\/doi.org\/10.1371\/journal.pone.0294236","journal-title":"PLoS ONE"},{"issue":"1","key":"1913_CR28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2174\/1570161033386826","volume":"1","author":"CM Villal\u00f3n","year":"2003","unstructured":"Villal\u00f3n CM, Centuri\u00f3n D, Valdivia LF, de Vries P, Saxena PR (2003) Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol 1(1):71\u201384. https:\/\/doi.org\/10.2174\/1570161033386826","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"1913_CR29","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clpt.2006.03.011","volume":"80","author":"FH Vanmolkot","year":"2006","unstructured":"Vanmolkot FH, de Hoon JN (2006) Acute effects of sumatriptan on aortic blood pressure, stiffness, and pressure waveform. Clin Pharmacol Ther Jul 80(1):85\u201394. https:\/\/doi.org\/10.1016\/j.clpt.2006.03.011","journal-title":"Clin Pharmacol Ther Jul"},{"key":"1913_CR30","doi-asserted-by":"publisher","first-page":"215013272096368","DOI":"10.1177\/2150132720963680","volume":"11","author":"DW Dodick","year":"2020","unstructured":"Dodick DW, Shewale AS, Lipton RB et al (2020) Migraine patients with Cardiovascular Disease and contraindications: an analysis of real-world Claims Data. J Prim Care Community Health 11:2150132720963680. https:\/\/doi.org\/10.1177\/2150132720963680","journal-title":"J Prim Care Community Health"},{"issue":"3","key":"1913_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/head.13749","volume":"60","author":"HC Diener","year":"2020","unstructured":"Diener HC (2020) The risks or Lack Thereof of Migraine treatments in Vascular Disease. Headache 60(3):649\u2013653. https:\/\/doi.org\/10.1111\/head.13749","journal-title":"Headache"},{"issue":"9294","key":"1913_CR32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/s0140-6736(01)06711-3","volume":"358","author":"MD Ferrari","year":"2001","unstructured":"Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668\u20131675. https:\/\/doi.org\/10.1016\/s0140-6736(01)06711-3","journal-title":"Lancet"},{"issue":"1","key":"1913_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.cir.98.1.25","volume":"98","author":"A MaassenVanDenBrink","year":"1998","unstructured":"MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 98(1):25\u201330. https:\/\/doi.org\/10.1161\/01.cir.98.1.25","journal-title":"Circulation"},{"issue":"8","key":"1913_CR34","doi-asserted-by":"publisher","first-page":"ytad221","DOI":"10.1093\/ehjcr\/ytad221","volume":"7","author":"TJ Somers-Edgar","year":"2023","unstructured":"Somers-Edgar TJ, Shah J, Kueh A, Kasargod Prabhakar C (2023) Triptan-induced takotsubo syndrome: a case report. Eur Heart J Case Rep 7(8):ytad221. https:\/\/doi.org\/10.1093\/ehjcr\/ytad221","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"1913_CR35","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamaneurol.2023.5549","volume":"1","author":"CL Petersen","year":"2024","unstructured":"Petersen CL, Hougaard A, Gaist D, Hallas J (2024) Risk of stroke and myocardial infarction among initiators of triptans. JAMA Neurol 1(3):248\u2013254. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5549","journal-title":"JAMA Neurol"},{"issue":"12","key":"1913_CR36","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1212\/wnl.45.12.2274","volume":"45","author":"P O\u2019Connor","year":"1995","unstructured":"O\u2019Connor P, Gladstone P (1995) Oral sumatriptan-associated transmural myocardial infarction. Neurology 45(12):2274\u20132276. https:\/\/doi.org\/10.1212\/wnl.45.12.2274","journal-title":"Neurology"},{"issue":"8849","key":"1913_CR37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/0140-6736(93)93064-8","volume":"341","author":"JP Ottervanger","year":"1993","unstructured":"Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH (1993) Transmural myocardial infarction with sumatriptan. Lancet 341(8849):861\u2013862. https:\/\/doi.org\/10.1016\/0140-6736(93)93064-8","journal-title":"Lancet"},{"issue":"3","key":"1913_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s00210-005-1036-8","volume":"371","author":"VL Lucaites","year":"2005","unstructured":"Lucaites VL, Krushinski JH, Schaus JM, Audia JE, Nelson DL (2005) [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain. Naunyn Schmiedebergs Arch Pharmacol 371(3):178\u2013184. https:\/\/doi.org\/10.1007\/s00210-005-1036-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"1913_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1006\/exnr.1997.6749","volume":"150","author":"KL Hoskin","year":"1998","unstructured":"Hoskin KL, Goadsby PJ (1998) Comparison of more and less lipophilic serotonin (5HT1B\/1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 150(1):45\u201351. https:\/\/doi.org\/10.1006\/exnr.1997.6749","journal-title":"Exp Neurol"},{"issue":"1","key":"1913_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/17425255.2018.1416097","volume":"14","author":"A Gonz\u00e1lez-Hern\u00e1ndez","year":"2018","unstructured":"Gonz\u00e1lez-Hern\u00e1ndez A, Marichal-Cancino BA, MaassenVanDenBrink A, Villal\u00f3n CM (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 14(1):25\u201341. https:\/\/doi.org\/10.1080\/17425255.2018.1416097","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1913_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-013-0134-7","volume":"37","author":"TQ Nguyen","year":"2014","unstructured":"Nguyen TQ, Lewis JH (2014) Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS. Drug Saf 37(2):109\u2013121. https:\/\/doi.org\/10.1007\/s40264-013-0134-7","journal-title":"Drug Saf"},{"issue":"6","key":"1913_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","volume":"19","author":"B Zhao","year":"2023","unstructured":"Zhao B, Zhang X, Chen M, Wang Y (2023) A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting System (FAERS) database. Expert Opin Drug Metab Toxicol 19(6):381\u2013387. https:\/\/doi.org\/10.1080\/17425255.2023.2235267","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"21","key":"1913_CR43","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1177\/15353702231211860","volume":"248","author":"H Le","year":"2023","unstructured":"Le H, Hong H, Ge W et al (2023) A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database. Exp Biol Med (Maywood) 248(21):1944\u20131951. https:\/\/doi.org\/10.1177\/15353702231211860","journal-title":"Exp Biol Med (Maywood)"},{"key":"1913_CR44","doi-asserted-by":"publisher","first-page":"e080107","DOI":"10.1136\/bmj-2024-080107","volume":"386","author":"WK Karlsson","year":"2024","unstructured":"Karlsson WK, Ostinelli EG, Zhuang ZA et al (2024) Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ 386:e080107. https:\/\/doi.org\/10.1136\/bmj-2024-080107","journal-title":"BMJ"},{"key":"1913_CR45","doi-asserted-by":"publisher","first-page":"1431562","DOI":"10.3389\/fphar.2024.1431562","volume":"15","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Wu H, Huang Y, Liang T, Li H (2024) Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration\u2019s adverse event reporting system databases. Front Pharmacol 15:1431562. https:\/\/doi.org\/10.3389\/fphar.2024.1431562","journal-title":"Front Pharmacol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01913-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T06:02:04Z","timestamp":1732514524000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01913-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1913"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01913-0","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}